Only 22 novel drugs were approved by the U.S. Food & Drug Administration in 2016—way down from the 45 approved in 2015—and just six of the new entries are for treating or diagnosing cancer. Still, 2016 was far from a washout for oncology research. Here were some of the high points of the year in the war on cancer:
